A small-cap growth stock I’d buy with £1,000 today, and one I’d sell

The market fall has thrown up some undervalued growth shares, but how do you find your way through the maze of risk?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With interim results released Tuesday, dotDigital (LSE: DOTD) is in the business of providing software services to the digital marketing business. At around 86p today, the share price has more than five-bagged in five years, and the latest figures show why.

Revenue in the six months to 31 December grew by 25% to £18.8m, with adjusted EBITDA up 8% to £5.7m. The acquisition of Comapi in November caused a cash outflow of £10.7m, but that still left the company with cash of £10.5m at the halfway stage.

Software can be a fickle business. But dotDigital’s approach is to provide software as a service, expand its offering (the Comapi acquisition apparently “provides further progress towards fully-fledged omnichannel offering“), and build long-term customer relationships.

That should hopefully provide both stability and a grounding for long-term growth, as CEO Milan Pate said the firm has “further cemented our partnerships with Magento, Shopify, Microsoft and our other partners.

Cash prospects

That strategy leads to recurring revenue streams and strong cash generation, and I think we could be looking at one of tomorrow’s big cash cows here. Dividends are currently only yielding under 1%, but that’s covered more than four times by earnings, and it’s progressive. From 0.1p per share in 2013, a dividend of 0.68p is forecast for the current year.

It does lead to my one caution that’s common with growth stocks. When a company starts to reach maturity and the transition from an all-out growth story to the beginnings of an income investment, the growth investors often dump it and the share price takes a knock.

But I like the long-term look of dotDigital, and I don’t see a 2019 P/E of 24 as too demanding.

Bigger risk

An example of a ‘jam tomorrow’ lossmaker that I’d steer clear of right now is Verona Pharma (LSE: VRP), but I want to start by telling you what I like about it.

Verona focuses on “developing and commercialising innovative therapies for respiratory diseases,” and 2017 results looked promising — for a start-up still in its cash-burn phase, at least.

Clinical studies sound impressive, with two having recently completed ahead of schedule. The firm’s RPL554 treatment for COPD, when used alongside Tiotropium, gave positive results including “significant and clinically meaningful additional improvement in peak lung function” and faster onset of action. It was well tolerated too, which is a key achievement.

Verona also raised £70m in the period, from a combination of a successful IPO on the Nasdaq Global Market, together with a European private placement and a shareholder private placement. That, especially the Nasdaq launch, suggests that some serious investors see great promise here.

Risky finances

I was bullish a year ago, but finances put me off now. A reported operating loss of £29.8m was due to the costs of these clinical trials and to pre-clinical activities, and the firm did end the year with £80.3m in cash and equivalents on the books.

But net cash used in operating activities ramped up to £20.7m (from £5.6m), and there are pre-tax losses of more than £30m per year currently forecast for the next two years.

That increases the likelihood of further cash being needed before profits come around, and with the pitfalls that can beset the pharma business right up until the last minute, the risk is too great for me.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. Teresa Kersten is an employee of LinkedIn and is a member of The Motley Fool’s board of directors. LinkedIn is owned by Microsoft. The Motley Fool UK owns shares of and has recommended Shopify. The Motley Fool UK has recommended dotDigital Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »